Latigo Biotherapeutics Inc

📅 Upcoming

🕒 Recent(90d)

News

• BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs
  BlossomHill Therapeutics will use its $150 million IPO proceeds to power the Phase 1/2 development of a non-small cell lung cancer drug, while Latigo Therapeutics will bring in more than $345 milli…
  biospace · 1d ago
• Latigo IPO raises nearly $350M for pain drug development
  The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.
  biopharma_dive · 4d ago
• BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
  Two growing biotechs blasted through their IPO expectations Friday, with Blossom Hill Therapeutics and Latigo Biotherapeutics each raising at least 30% more than expected in their stock market debuts.
  fiercebiotech · 4d ago
• Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
  Latigo Biotherapeutics has fleshed out its plans for an IPO to finance the development of its clinical-stage pipeline of non-opioid pain management drugs.
  fiercebiotech · 8d ago
• Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trial
  Latigo Biotherapeutics said its non-opioid drug reduced acute pain in a Phase 2b study, as the company seeks to compete with Vertex Pharmaceuticals’ approved pain treatment Journavx. Next, Latigo h…
  endpoints · 12d ago
• STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
  Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the market
  stat · 13d ago
• Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
  In vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.
  fiercebiotech · 19d ago
• Pain drugmaker Latigo outlines plans to go public
  The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.
  biopharma_dive · 22d ago
• Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
  Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing.
  fiercebiotech · 22d ago
• Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
  Latigo Biotherapeutics is preparing to go public in order to bankroll the development of its clinical-stage pipeline of non-opioid pain management drugs.
  fiercebiotech · 23d ago